



AGENDA/LIST OF TALKS/INDEX

	<u>Approx. Minutes</u>
<u>MODULE 1: Intro HIV</u>	
Global HIV Epidemiology, Cascade of Care Thomas Quinn, MD	20
HIV Diagnostics and Initial Testing Recommendations Joyce Jones, MD, MS	20
HIV Prevention: Behavioral Interventions, Blood Supply, Risk Reduction Among IDU, Viral Suppression Seun Falade, MBBS, MPH	20
Mechanisms of HIV Transmission Amanda Rosencrans, MD, MHS	20
<u>MODULE 2: HIV Immunology & Pathogenesis</u>	<u>Approx. Minutes</u>
Understanding the HIV Viral Life Cycle Eileen Scully, MD, PhD	15
HIV and the Latent Reservoir Francesco Simonetti, MBCHB, PhD	20
HIV Immunology, Progression, Pathogenesis Joel Blankson, MD, PhD	20
Emerging Concepts in HIV Cure Francesco Simonetti, MBCHB, PhD	20
<u>MODULE 3: ART Core Concepts</u>	<u>Approx. Minutes</u>
ART Primer Joyce Jones, MD, MS	10
Initial ART Sonya Krishnan, MD	15
Common Drug Interactions in ART Selection Christin Kilcrease, PharmD	15
Practical Considerations in Usage of LAI Therapy Christin Kilcrease, PharmD	15
Understanding ARV Resistance Eileen Scully, MD, PhD	20
Managing Treatment Failure Sonya Krishnan, MD	15
Treatment Optimization/Simplification and Long Acting Injectables Ethel Weld, MD, PhD	15
HIV-ASSIST Maunank Shah, MD, PhD	20
Case-Based: Regimen Selection with Heavily Treatment Experienced Patients Joel Gallant, MD, PhD	20
<u>MODULE 4: Comorbidities and Complications of HIV</u>	<u>Approx. Minutes</u>
Neurological Complications and Opportunistic Infections Arun Venkatesan, MD, PhD	20
Cardiovascular Considerations of HIV Wendy Post, MD, MS	20
Metabolic Considerations of HIV Todd Brown, MD, PhD	20



The Twin Goals of HIV Management in Pregnancy: Optimal Treatment of the Mother and Prevention of Mother to Child Transmission (PMTCT)	20
Jean Anderson, MD	
Renal and Bone Considerations	30
Todd Brown, MD, PhD	
HIV-related Malignancies	20
Christine Durand, MD	
<u>MODULE 5: Common Opportunistic Infections</u>	<u>Approx. Minutes</u>
Tuberculosis Disease	15
Jeff Tornheim, MD, MPH	
Pneumocystis Jirovecii Pneumonia	15
Sonya Krishnan, MD	
Mycobacterium Avium-Intracellulare	15
Christopher Lippincott, MD, MPH	
Cryptococcus	20
John Baddley, MD, MSPH	
Histoplasmosis	15
John Baddley, MD, MSPH	
HHV-8 Related Disease	15
Ramya Ramaswami, MBBS, MPH	
Progressive Multifocal Leukoencephalopathy	10
Natasha Chida, MD, MSPH	
Cytomegalovirus	15
Natasha Chida, MD, MSPH	
Toxoplasmosis	15
Leon Lai, MD	
Mucocutaneous Manifestations of AIDS/Advanced HIV Disease	20
Adam Lipworth, MD	
Mucocutaneous Drug Reactions and IRIS	20
Adam Lipworth, MD	
Immune Reconstitution Inflammatory Disease	15
Irini Sereti, MD	
<u>MODULE 6: Primary Care Considerations</u>	<u>Approx. Minutes</u>
Overview of Vaccination	20
Michael Rose, MD	
Mucocutaneous Disease in People Living with Well-Controlled HIV	20
Adam Lipworth, MD	
Substance Use Disorder and Addiction Medicine	15
Michael Fingerhood, MD	
Neurocognitive and Mental Health Screening	15
Thomas Laskow, MD	
Gender Affirming Care	20
Jill Crank, CRNP	
Anal Dysplasia	15
Maaza Abdi, MD	
HPV Disease in Women	15
Jean Keller, PA-C	



Foundations in HIV Medicine
April 1, 2025 – March 31, 2028
80067991-59128

MODULE 7: PrEP

Review of Oral PrEP Guidelines: US, Europe, WHO

Sunil Solomon, MD

Prevention: Basics of PrEP

Joyce Jones, MD, MS

Injectable PrEP Guidelines and Latest Data on LEN

Greg Lucas, MD, PhD

PrEP Guidelines for PWID

Greg Lucas, MD, PhD

Approx. Minutes

15

20

15

10

MODULE 8: Co-Infections

Diagnosis and Monitoring of Hepatitis C Virus

Mark Sulkowski, MD

Contemporary Treatment of Hepatitis C Virus

Mark Sulkowski, MD

Diagnosis and Monitoring of Hepatitis B Virus

Chloe Thio, MD

Treatment Considerations for Hepatitis B Virus

Chloe Thio, MD

LTBI Diagnosis

Maunank Shah, MD, PhD

LTBI Treatment and Monitoring

Jeff Tornheim, MD, MPH

HIV and HCV Coinfection Considerations

Mark Sulkowski, MD

HIV and HBV Coinfection Considerations

Chloe Thio, MD

HIV and LTBI Coinfection Considerations

Sonya Krishnan, MD

Approx. Minutes

20

15

20

15

15

20

10

10

10